Insights on localized and systemic delivery of redox-based therapeutics by Buglak, N.E. et al.
Review Article
Insights on Localized and Systemic Delivery of
Redox-Based Therapeutics
Nicholas E. Buglak ,1,2,3 Elena V. Batrakova,2,4 Roberto Mota,1,2
and Edward S. M. Bahnson 1,2,3,5
1Department of Surgery, Division of Vascular Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
3Curriculum in Toxicology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
4Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill,
NC 27599, USA
5Department of Cell Biology & Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Correspondence should be addressed to Edward S. M. Bahnson; edward_bahnson@med.unc.edu
Received 30 October 2017; Accepted 18 December 2017; Published 14 February 2018
Academic Editor: Maria C. Franco
Copyright © 2018 Nicholas E. Buglak et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in anymedium, provided the original work is properly cited.
Reactive oxygen and nitrogen species are indispensable in cellular physiology and signaling. Overproduction of these reactive
species or failure to maintain their levels within the physiological range results in cellular redox dysfunction, often termed
cellular oxidative stress. Redox dysfunction in turn is at the molecular basis of disease etiology and progression. Accordingly,
antioxidant intervention to restore redox homeostasis has been pursued as a therapeutic strategy for cardiovascular disease,
cancer, and neurodegenerative disorders among many others. Despite preliminary success in cellular and animal models, redox-
based interventions have virtually been ineffective in clinical trials. We propose the fundamental reason for their failure is a
flawed delivery approach. Namely, systemic delivery for a geographically local disease limits the effectiveness of the antioxidant.
We take a critical look at the literature and evaluate successful and unsuccessful approaches to translation of redox intervention
to the clinical arena, including dose, patient selection, and delivery approach. We argue that when interpreting a failed
antioxidant-based clinical trial, it is crucial to take into account these variables and importantly, whether the drug had an effect
on the redox status. Finally, we propose that local and targeted delivery hold promise to translate redox-based therapies from
the bench to the bedside.
1. Introduction
Redox reactions are at the center of cellular metabolism and
signaling and result in the production of reactive species
[1]. Reactive species that stem from oxygen reduction
reactions are called reactive oxygen species (ROS) and
include free radical and nonradical molecules such as
hydroxyl radical (HO•), peroxyl (RO2
•), superoxide (O2
•−),
singlet oxygen (1O2), and hydrogen peroxide (H2O2) [2].
Reactive species that stem from nitric oxide metabolism
are called reactive nitrogen species (RNS) and include free
radical and nonradical molecules such as nitric oxide
(•NO) itself, nitrite (NO2
−), nitrogen dioxide (•NO2),
peroxynitrite (ONOO−), dinitrogen trioxide (N2O3), and
alky peroxynitrite (ONOOR) [2]. These species are highly
reactive and therefore are capable of forming reversible and
irreversible interactions with many different macromolecules
throughout the body. Under physiological conditions, the
reactive species are in balance with antioxidant defenses
which enzymatically and nonenzymatically maintain redox
homeostasis. In homeostasis, reactive species fulfill their
critical role in cell signaling, migration, proliferation, and
metabolism. If the redox balance is skewed towards the
reactive species however, either from their overproduction
or antioxidant depletion, a pathological condition can ensue.
Exposure to cigarette smoke [3], various air pollutants [4, 5],
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UV radiation [6], xenobiotics [7], alcohol consumption [8],
and different diseases can further exacerbate the pathological
cellular state. Consequently, the prolonged redox imbalance
can cause aberrant DNA modifications [9], lipid peroxida-
tion [10], peptide chain fragmentation [11], and alterations
in signal transduction [12]. This state of cellular redox imbal-
ance, as ROS and RNS overwhelm defense mechanisms, is
often referred to as oxidative stress.
Disruption in redox homeostasis can result in undesir-
able molecular interactions throughout the cell. Impairment
at the molecular level can lead to defective organelles, which
can translate into cellular dysfunction. In turn, this can cause
tissue incompetence ultimately resulting in the development
of organ-specific or systemic disease. For this reason, a com-
ponent of redox dysfunction has been linked to almost all
disease states [13, 14] including asthma, hypertension, carci-
noma, leukemia, diabetes, Alzheimer’s disease, autoimmu-
nity, and infection. The implication of a causative role of
ROS and RNS in disease development has led to many
studies and clinical trials using antioxidant molecules as
therapeutics. Despite our understanding of the biochemical
interaction of reactive species and their associations with
disease onset, causality has yet to be fully elucidated. It is
because of this poorly understood and missing connection
that most redox-based therapies have largely been unsuccess-
ful. For the purposes of this review, we evaluate the research
with the assumption that reactive species have a causal role in
disease onset. Accordingly, we chose to review a range of
redox-based molecules, from micronutrients, which have
been trialed for decades, to new and emerging small
molecules currently entering clinical trials for the first time.
Additionally, we highlight cell-mediated drug delivery as a
novel approach for administering these therapeutics. Ulti-
mately, this review aims to rationalize the reasons as to why
few redox-based therapies succeed.
2. Localized and Targeted versus Systemic
Therapy Application
Failure of therapies to date can be attributed to improper
route of drug administration, a discrepancy between preven-
tative and remission therapy, wrong dose to achieve desired
effect, or the wrong choice in redox-active molecule due to
the vast array of reactive moieties between redox-active
compounds. We propose that a fundamental issue with most
therapeutic approaches up to now has been their method of
delivery. For instance, systemic delivery of an antioxidant
for the treatment of a geographically local redox imbalance,
as with tumors or atherosclerotic lesions, simply may not
deliver the therapeutic concentration to the diseased site.
The route of administration may not have been fully evalu-
ated or the metabolism of that antioxidant formulation may
not have been properly understood before trials began.
Moreover, the redox-active therapeutic may interact with
and disrupt systems currently at redox homeostasis. This
could lead to a state of local reductive or oxidative stress
outside of the diseased area as many “antioxidants” have a
prooxidant capacity depending on their concentration and
redox environment. Following this notion, systemic delivery
of antioxidants to treat a disease with systemic redox
imbalance, as in diabetes, may yield the desirable effect. For
conditions with localized redox imbalance, however, we
suggest the necessity of developing locally delivered or
targeted therapeutic strategies that deliver the redox inter-
vention directly and preferentially to the site of disease,
hence addressing the redox dysfunction in a local and
targeted manner.
3. Micronutrients
Micronutrients are readily obtained through the diet and
were among the first molecules with antioxidant properties
to be identified. Their chemical structures have redox-
sensitive functional groups or radical scavenging moieties.
Additionally, some have the capacity to recycle endoge-
nous antioxidants. These molecules were also the first to
be trialed as therapeutics. Herein, we discuss several recent
trials with the ubiquitous alpha-lipoic acid as well as vitamins
A, B12, C, and E.
3.1. Vitamin C. Vitamin C, also known as ascorbic acid or
ascorbate, is a water-soluble compound synthesized from
glucose by most animals and galactose by plants. Humans
and apes are among the few animals that lack the key enzyme
required for vitamin C biosynthesis, L-gulonolactone oxidase
[15]. As such, ascorbate is obtained externally through the
diet or by supplementation. Among its many physiological
functions, ascorbate acts as a cofactor for neurotransmitter
synthesis as well as collagen synthesis and maintenance
[16]. As an antioxidant, ascorbate is capable of recycling
oxidized vitamin E to its reduced form [17] and scavenging
many different ROS and RNS. The preclinical and clinical
studies discussed herein are summarized in Table 1.
Work done by Schoenfeld et al. [18] revitalized the
therapeutic potential of ascorbate in treating cancer by
describing a potential new mechanism in non-small-cell lung
cancer (NSCLC) and glioblastoma (GBM). Cellular work
using two NSCLC and two GBM cell lines showed that
ascorbate selectively sensitizes these cancer cells to chemo-
therapeutics and radiation therapy compared to primary
bronchial epithelial cells and normal human astrocytes [18].
As previously mentioned, antioxidants can have a prooxidant
capacity depending on their redox environment. Here,
ascorbate treatment increased steady-state levels of hydrogen
peroxide (H2O2) and labile iron levels in both cancer cell
types, but not in noncancerous cells [18]. The enhanced
cancer cell-ascorbate toxicity could be inhibited by preincu-
bation with iron chelators or with catalase, which breaks
down H2O2. Meanwhile, preincubation with EDTA [18], a
known enhancer of iron redox cycling, further increased
cancer cell-specific toxicity. Lane et al. [19] reported that
ascorbate may also increase intracellular iron uptake by
acting on transferrin receptors. The cancer-specific toxicity
in vitro was recapitulated in mouse xenograft models by
Schoenfeld et al. [18] for both NSCLC and GBM using
combinations of radiochemotherapy with intraperitoneal
injections of ascorbate. Animals treated with all three thera-
pies, compared to radiochemotherapy or ascorbate alone,
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exhibited an increased rate of survival [18]. The authors
proposed a mechanism inherent to cancer cells whereby
superoxide (O2
•−) and H2O2 disrupt cellular iron metabolism
with ascorbate oxidation further increasing intracellular
H2O2 and labile iron levels. Through the Fenton reaction,
H2O2 and iron react causing an increased oxidative burden
and resulting in the observed cancer-specific ascorbate
toxicity [18]. A phase I clinical trial for GBM patients treated
with radiation, temozolomide, and intravenous ascorbate
infusions showed that ascorbate was well tolerated and
increased the average progression-free survival compared to
the historical median [18]. Additionally, a phase II clinical
trial for NSCLC patients treated with chemotherapy and
ascorbate infusions reported an increased disease control rate
compared with historical controls [18]. Unfortunately, the
efficacy of ascorbate infusions in concert with radiochemo-
therapy has yet to be determined due to the limited sample
size in these two studies.
The ability of ascorbate to specifically target NSCLC and
GBM cancer cells without affecting the redox homeostasis of
healthy cells makes systemic intravenous administration
possible. In this example, the redox modulation happens only
in tumor cells where iron metabolism is disrupted, and in
this sense, this is an example of targeted therapy. How-
ever, a consistent plasma concentration must be main-
tained and 20mM has been proposed as the therapeutic
optimum [20]. Meanwhile, oral administration is incapable
of obtaining and maintaining the required plasma concentra-
tions [21, 22]. These data show the importance of adminis-
tration route to achieve the desired effect. In the PACMAN
study, a phase I clinical trial for stage IV pancreatic cancer,
Welsh et al. [23] showed that infusion of high doses of ascor-
bate together with gemcitabine achieved stable plasma levels
around 20mM. The PACMAN study also revealed that
systemically administered ascorbate did not cause an alter-
ation in the erythrocyte reduced to oxidized glutathione
(GSH:GSSG) ratio nor in plasma levels of F2-isoprostane
[23], an arachidonic acid peroxidation product commonly
used as a biomarker. The mean survival was 12 months,
almost double the historic median for gemcitabine-treated
patients [23], yet due to the small sample size, no statistically
significant conclusion about efficacy can be made. As of
June 2017, the PACMAN study is scheduled to enter
phase II (NCT02905578), with phase II trials for NSCLC
(NCT02905591) and GBM (NCT02344355) scheduled as
well. Hopefully, these upcoming and future trials will identify
if an intravenous vitamin C formulation is an effective
targeted systemic delivery for treating a geographically local
redox imbalance.
3.2. Vitamin E. E vitamins are a group of fat-soluble com-
pounds classified as saturated tocopherols or unsaturated
tocotrienols, with α, β, γ, and δ isoforms within each group.
The most biologically active vitamin E compound in humans
is α-tocopherol. Therefore, α-tocopherol will be the vitamin
E isoform described henceforth unless otherwise specified.
Interestingly, vitamin E has been hypothesized to act only
as a peroxyl (RO2
•) radical scavenger [17, 24]. As such,
vitamin E effectively prevents the peroxyl radical chain
reaction-driven lipid peroxidation. A summary of the pre-
clinical and clinical studies discussed can be seen in Table 2.
Being fat soluble, vitamin E is mainly transported
by lipoproteins where it prevents lipoprotein oxidation
[25]—a redox reaction that drives atherosclerotic plaque
development. An atherosclerosis model of rabbits fed a high-
cholesterol diet showed that dietary vitamin E supplementa-
tion significantly reduced plaque development [26]. Tang
et al. showed that vitamin E supplementation reduced pla-
que development in apolipoprotein E knockout (ApoE−/−)
mice when administered early, between 6 and 22 weeks of
age, yet had no effect on reducing advanced lesions when
administered at 30 or 38 weeks [27]. It is worth noting
here that α-tocopherol has been shown to have limited
antiatherosclerotic potential in rodent models [28]. In both
the rabbit model and the ApoE−/− mice, vitamin E activated
the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway




In vitro Pancreatic cancer cell H2O2 production increases susceptibility to therapeutic effect of vitamin C [20]
I.P.
Maintaining a 20mM plasma concentration of vitamin C is optimal to obtain a therapeutic effect from
vitamin C in an induced-tumor mouse model
[20]
In vitro Vitamin C increases intracellular iron uptake in HUVECs as well as in multiple human cancer cell lines [19]
In vitro
Vitamin C selectively sensitizes non-small-cell lung cancer and glioblastoma cells to radiation and





Orally administered vitamin C unable to maintain therapeutic plasma concentration [21]
15–125 g
I.V.
High-dose infusion of vitamin C with gemcitabine in stage IV pancreatic cancer patients could achieve




Vitamin C infusions were well tolerated and increased average progression-free survival in glioblastoma
patients and control rate of disease in non-small-cell lung cancer patients
[18]
I.P.: intraperitoneal; I.V.: intravenous.
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[26, 27], which regulates the expression of antioxidant
enzymes [29]. Specifically, Bozaykut et al. [26] showed
an increase in the expression of glutathione S-transferase,
one downstream enzyme of Nrf2, which is responsible
for initiating the function of glutathione (GSH) [30],
another major intracellular antioxidant. The Nrf2 pathway
has now also been implicated as a vitamin E therapeutic
mechanism in in vitro models of cancer [31] and macular
degeneration [32] as well as in in vivo allergy [33] and
developmental [34] studies. Furthermore, vitamin E has
also been shown to increase peroxisome proliferator-
activated receptor gamma (PPARγ) expression [26, 27].
PPARγ is one isoform of the PPAR ligand-activated tran-
scription factors whose activation can be protective against
cardiovascular diseases, neurodegenerative disorders, and
cancer [35–37]. Thus, Nrf2 and PPAR activation reveal
indirect antioxidant properties of vitamin E, which when
paired with the direct radical scavenging ability make for
a promising therapeutic.
CHAOS [38] and HOPE [39] were two of the first trials
using vitamin E in prevention of cardiovascular disease. Both
of these trials showed no cardiovascular benefit, which can
potentially be attributed to the 400 IU/day [39] or up to
800 IU/day [38] doses used. In 2007, Roberts et al. [40]
conducted both a dose-ranging and time-course study in
hypercholesterolemic patients to evaluate the pharmacology
of vitamin E. This was a beneficial study for future clinical
trials as they revealed two critical dosing aspects. First, it took
16 weeks of daily dosing to reduce the plasma F2-isoprostane
concentration [40]. Second, this reduction was only signifi-
cantly obtained at 1600 IU/day and 3200 IU/day, with a trend
towards reduction at 800 IU/day [40]. At the largest dose of
natural vitamin E (3200 IU/day), there was a 49% reduction
in plasma F2-isoprostanes, which led the authors to suggest





α-Tocopherol activates Nrf2 in human retinal pigment epithelial cell line ARPE-19, thus inducing
transcription of phase II enzymes
[32]
Oral




α-Tocopheryl succinate activates Nrf2 in PC3 prostate cancer cell line which inhibits NF-κB nuclear




Vitamin E significantly reduced atherosclerotic plaque progression in rabbits fed a high-cholesterol diet [26]
Oral Vitamin E significantly reduced atherosclerotic plaque progression in ApoE−/− mice [27]
Oral
Vitamin E deficiency disrupts grass carp growth and physiology while vitamin E supplementation is able to





Daily vitamin E supplementation showed substantial reduction in nonfatal myocardial infarction in patients





4–6 years of daily vitamin E supplementation showed no therapeutic benefit on cardiovascular events in




16 weeks of at least 800 IU/day of vitamin E required to reduce the plasma F2-isoprostane concentration [40]
400 IU
Oral










Patients with Down syndrome had their abnormal superoxide dismutase and catalase activity as well as low




Daily high dose of vitamin E slowed the functional decline of Alzheimer’s disease patients [46]
400 IU
Oral
Eight weeks of daily vitamin E supplementation increased paraoxonase-1 enzyme activity but did not lower




Three months of daily vitamin E supplementation significantly reduced serum malondialdehyde levels in




Patients undergoing colorectal cancer surgery exposed to vitamin E at the surgical site experienced a reduced
rate of surgical site infection and lowered inflammatory response
[47]
I.M.: intramuscular; S.C.: subcutaneous.
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that the antioxidant potency of vitamin E may not be biolog-
ically effective [40]. These studies taken together underline
the relevance of selecting the appropriate dose and regimen
to achieve a significant effect on redox homeostasis. Only
after determining that a treatment actually improves redox
function can we assess its antioxidant effect on disease pro-
gression and clinical outcomes. A study by Milman et al.
[41] showed that daily vitamin E supplementation only had
cardiovascular benefit in type 2 diabetics having a haptoglo-
bin 2-2 genotype. The protein produced by this genotype is
associated with elevated systemic oxidative stress due to its
inferior function compared to the haptoglobin 1-1 genotype
protein product. Several studies measured serum malon-
dialdehyde (MDA) levels, a lipid peroxidation product, to
assess the benefit of oral vitamin E supplementation.
Although a reduction in plasma MDA levels was frequently
observed, this systemic decrease in a lipid peroxidation
marker did not correlate with improvement of clinical symp-
toms [42–44]. Thus, translating cellular and animal model
work into an effective human therapeutic while also identify-
ing the proper patient population that benefits from the given
therapy and relevant biomarkers makes clinical trial design
rather difficult.
Patients with ranging neurological disorders have been
reported to experience increased levels of systemic oxidative
stress [13]. Parisotto et al. [45] compared the blood antioxi-
dant status of children with Down syndrome (DS) before
and after 6 months of daily vitamin C and E supplementa-
tion. The study showed that DS patients had elevated
superoxide dismutase (SOD) and catalase activity yet lower
GSH levels, and all could be returned to physiological
levels after supplementation [45]. A randomized, double-
blind, placebo-controlled, parallel-group trial reported that
a high dose of 2000 IU/day of vitamin E slowed the
functional decline of patients with mild to moderate Alzhei-
mer’s disease [46]. Both studies highlight how a systemically
administered antioxidant can reduce systemic redox imbal-
ance and alleviate symptoms experienced by individuals
with neurological disease.
Lastly, Alias et al. [47] showed that subcutaneous
application of vitamin E acetate ointment reduced the rate
of surgical site infection in colorectal cancer surgery patients,
while simultaneously lowering the inflammatory response.
The patients underwent a laparoscopic, or minimally inva-
sive, surgery. Patients who received vitamin E treatment
had decreased C-reactive protein and a reduced white blood
cell count 48 hours after surgery and reported lower post-
operative pain [47]. This is an excellent example of a pre-
ventative strategy for localized delivery of an antioxidant
to mitigate the onset of local redox imbalance.
3.3. Alpha-Lipoic Acid. The disulfide fatty acid α-lipoic acid
(ALA) is an amphipathic molecule both naturally synthe-
sized and obtained through the diet. Virtually ubiquitous
throughout the body, ALA and its reduced form, dihydroli-
poic acid, have been reported to have numerous antioxidant
and anti-inflammatory properties [48]. The therapeutic
potential thus stems from the capability of ALA to scavenge
reactive species [49, 50], recycle glutathione (GSH) and
vitamins C and E [49], chelate divalent transient metal ions
[50], and increase glucose uptake [51]. The preclinical and
clinical studies described from here on are summarized
in Table 3.
Goraca et al. [52] evaluated ALA treatment in a rat model
of bacterial infection using lipopolysaccharide (LPS), a major
component of the outer membrane of gram-negative bac-
teria. The spleen of LPS-treated rats had increased levels
of hydrogen peroxide (H2O2) and lipid peroxidation, an




Oral ALA slowed the rate of plaque progression in a diet-induced rabbit atherosclerosis model [56]
I.P.
ALA reduced lesion size in a diet-induced atherosclerotic mouse model. ALA also reduced vascular smooth
muscle cell proliferation and migration in vitro
[59]
I.V.
Spleen weight/body weight ratio, levels of H2O2, lipid peroxidation, and levels of reduced glutathione
returned to physiological levels in LPS-treated rats following ALA injection
[52]
Oral
ALA restored GSH, SOD, and catalase plasma concentrations to physiological levels in a pesticide-induced
oxidative stress rat model
[54]
S.C.
ALA restored SOD and catalase concentrations to physiological levels in brain tissue of a phenylketonuria
rat model
[55]









Four years of daily ALA supplementation improved neuropathic conditions of diabetics suffering from




20 weeks of daily ALA supplementation alleviated the pain experienced by diabetics suffering
from polyneuropathy
[62]
I.P.: intraperitoneal; I.V.: intravenous; S.C.: subcutaneous.
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increased spleen weight/body weight ratio, and decreased
levels of GSH [52]. All three of these markers were returned
to physiological levels after intravenous ALA injection [52]
suggesting that ALA can protect the spleen from an exagger-
ated inflammatory response. Cimolai et al. [53] showed that
intraperitoneal-injected ALA could restore kidney mito-
chondrial function in rats exposed to LPS. Mignini et al.
[54] used a pesticide-induced oxidative stress rat model to
evaluate the effects of oral ALA supplementation and showed
that ALA could increase plasma GSH concentrations. Addi-
tionally, ALA restored SOD and catalase plasma concentra-
tions to physiological levels [54]. Subcutaneous delivery of
ALA restored SOD and catalase to physiological levels in
the brain tissue of a phenylketonuria rat model [55], a
neurological disease that causes systemic phenylalanine
accumulation and oxidative stress. Orally administered
ALA slowed the rate of plaque progression, lowered
plasma F2-isoprostane levels, decreased lipid accumula-
tion, and reduced collagen deposition in a diet-induced
rabbit atherosclerosis model [56]. Furthermore, ALA
decreased mRNA expression of vascular cell adhesion
molecule-1 (VCAM-1) and of intracellular adhesion
molecule-1 (ICAM-1) and reduced NF-κB pathway activity
in the rabbit model [56]; all of which are proinflammatory
factors associated with plaque development [57, 58]. A diet-
induced atherosclerotic mouse model also showed that
intraperitoneal ALA delivery could reduce lesion size and
VCAM-1 and ICAM-1 expression [59]. Lee et al. [59]
showed that ALA could reduce vascular smooth muscle
proliferation and migration in vitro by attenuating the
Ras-MEK1/2-ERK1/2 proliferative pathway. As of June
2017, phase III clinical trials using ALA for atherosclerosis
treatment (NCT00764270) and heart disease prevention
(NCT00765310) are ongoing.
ALA supplementation has been particularly successful in
diabetic patients and has been prescribed for the treatment of
diabetic polyneuropathy in Germany for decades [50]. In
2004, Ziegler et al. [60] assessed the role of oxidative stress
in the development of diabetic polyneuropathy, a complex
neuronal disorder associated with increased morbidity and
mortality. Their results showed that systemic redox imbal-
ance was more prominent in diabetics with polyneuropathy
than in diabetics without polyneuropathy [60]. The SYDNEY
2 clinical trial assessed the efficacy of orally administered
ALA in alleviating pain experienced by diabetic patients with
distal symmetric polyneuropathy [61]. The primary mea-
surement in the SYDNEY 2 trial was total symptom score
(TSS), a summation of factors related to neuropathic pain
where higher scores indicate an increased level of experi-
enced pain. The results revealed that 600mg of ALA admin-
istered orally for 5 weeks improved the positive sensory
symptoms of diabetic patients [61]. Similar findings were
described by Garcia-Alcala et al., [62] who reported that 20
weeks of ALA treatment resulted in a continuous reduction
in TSS. NATHAN 1 was a four-year clinical trial that further
assessed ALA treatment for polyneuropathy as well as the
safety of prolonged oral administration of 600mg of ALA
[63]. This trial used several comprehensive analyses along-
side TSS such as the neuropathy impairment score (NIS)
[64] and the NIS lower limbs score to measure therapeutic
outcomes without any direct measurements of changes in
redox markers. Improvement of neuropathic impairments,
particularly small fiber and muscular function, was ulti-
mately reported, and the 600mg dose was well tolerated by
patients [63]. We guide the readers to an extensive review
by Papanas and Ziegler [65] of more trials and relevant
meta-analyses regarding ALA in diabetic neuropathy. The
success seen in these trials can likely be attributed to the
hydrophilic and lipophilic nature of ALA as well as to the
delivery route in treating a disorder that stems from a
systemic redox imbalance.
3.4. Vitamin A. A vitamins are a group of unsaturated, fat-
soluble organic molecules that elicit pleiotropic effects
throughout the body. Physiologically, vitamin A regulates
energy homeostasis, lipid metabolism, the immune response,
and gene expression for cellular development and differenti-
ation [66–68]. The major signaling mechanism for the
regulatory actions of vitamin A is through nuclear retinoic
acid receptors. However, signaling through Janus kinase
(JAK)/signal transducer and activator of transcription
(STAT), mitogen-activated protein kinase (MAPK), and
PPAR pathways have also been described [67]. Vitamin A
quenches singlet oxygen (1O2) [69] and prevents lipid per-
oxidation by scavenging peroxyl (RO2
•) radicals [70], simi-
lar to vitamin E. Furthermore, the major active metabolite
of vitamin A—retinoic acid—acts as a precursor for rho-
dopsin, the light-sensitive pigment in the eye responsible
for phototransduction [71]. Retinoic acid is obtained
through the diet from animal-derived food or from plant-
derived precursors like β-carotene and lycopene. Clinical
studies using vitamin A are summarized in Table 4.
In accordance with the pleiotropic properties on cel-
lular homeostasis, vitamin A was trialed and is now
accepted as a therapeutic for various skin-related condi-
tions. Topically applied β-carotene protected human skin
from IR-generated reactive species [72] and orally adminis-
tered β-carotene reduced UV-induced skin lesions [73]. A
randomized, double-blind, vehicle-controlled, clinical trial
showed that topical retinol, the alcohol retinoic acid deriva-
tive, applied three times a week for 24 weeks reduced the
appearance of aging-related fine wrinkles in elderly volun-
teers by increasing the dermal matrix [74]. Furthermore,
topical application of tretinoin or all-trans retinoic acid has
long been prescribed for the treatment of acne and photoag-
ing [75, 76] and is more effective than orally administered
tretinoin in cases of photoaging [77]. The role of these and
more vitamin A derivatives in treating skin disease has been
reviewed elsewhere [78]. The success of topical vitamin A
application provides evidence that identifying the proper
antioxidant for a given condition combined with an adminis-
tration route that localizes the redox intervention results in a
successful antioxidant therapy.
3.5. Vitamin B12. Vitamin B12 derivatives or cobalamins
(Cbl) are soluble macrocycles belonging to the corrinoid
family with a cobalt atom tethered in the center of the corrin
plane. They are essential cofactors for two enzymes in
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mammals: mitochondrial methylmalonyl-CoA mutase and
cytosolic methionine synthase. The central cobalt can change
its oxidation state between +3 (cob(III)alamin), +2 (cob(II)a-
lamin), and +1(cob(I)alamin), which makes these com-
pounds redox active. Moreover, it has been shown that Cbl
reacts with O2
•− at rates comparable with that of superoxide
dismutase [79, 80]. Hence, it has been suggested that cobala-
mins modulate inflammation and redox status [81–83] in
addition to and independently of their cofactor function.
Low serum levels of B12 are prevalent in patients with type
2 diabetes mellitus, and there is an association between low
levels of B12 and markers of oxidative dysfunction [84].
Moreover, levels of B12 negatively correlate with fasting glu-
cose, oxidized LDL, and catalase levels in diabetic vegetarians
[85]. These findings suggest that Cbl supplementation could
be useful in patients with type 2 diabetes mellitus, especially if
they are vegetarians, who are at risk of low B12. Preclinical
and clinical work with vitamin B12 is summarized in Table 5.
Cobalamin is essential to metabolize homocysteine, an
independent risk factor for cardiovascular disease. Hence,
researchers have investigated the role of Cbl in cardiovascu-
lar disease. One of us was among the first to characterize a
redox effect in vascular cells [83] and suggest that it acted
by direct scavenging of O2
•− with a high rate constant [80].
In a randomized placebo-controlled trial, a mix of folate,
vitamin B6, and vitamin B12 reduced the carotid intima-
media thickness in patients at risk of cerebral ischemia [86].
This effect was found to be independent of homocysteine.
In a small prospective randomized placebo-controlled trial,
Willems et al. [87] demonstrated that treatment with
cobalamin in patients with coronary artery disease
improved volumetric coronary blood flow. These results





Pulse radiolysis determined that the rate constant between Cob(II)alamin and superoxide (O2
•−) is 6.8× 108 M−1 s−1,
which is within an order of magnitude of cytosolic and mitochondrial superoxide dismutase (SOD)
[79]
In vitro Cob(II)alamin reacts with O2
•− at a rate similar to that of the SOD [80]
In vitro
Cyanocobalamin treatment inhibited O2






Daily supplementation with folic acid, vitamin B6, and vitamin B12 for one year significantly reduced the carotid




Six months of daily folic acid and vitamin B12 supplementation improved coronary endothelial function in patients




Two years of daily supplementation with folic acid and vitamin B12 significantly increased coronary blood flow in





Daily ultrahigh-dose injections (25mg) of methylcobalamin improved the compound muscle action potentials of
patients with amyotrophic lateral sclerosis
[89]
Eyedrops
Eyedrops containing 0.15% hyaluronic acid and vitamin B12 reduced oxidative stress markers in the conjunctiva
(mucous membrane covering eye) and improved the overall symptoms of patients with chronic dry eye
[90]
I.M.: intramuscular.






12 weeks of daily oral vitamin A reduced UV-induced skin lesions [73]
0.4% lotion
Topical
Topical vitamin A application three times a week for 24 weeks reduced aging-related wrinkles [74]
0.2% lotion
Topical





Topical vitamin A more effective in treating photoaging than orally administered [77]
7Oxidative Medicine and Cellular Longevity
were later confirmed by Bleie et al. [88] showing an
increased coronary blood flow in a patient with stable
coronary artery disease treated with cobalamin, suggesting
that B12 improves vascular function.
Cobalamin levels are associated with systemic and central
nervous system (CNS) markers of redox dysfunction and
inflammation, independently of homocysteine levels [82].
In a controlled, double-blinded study in patients with
idiopathic osteoarthritis, Flynn et al. [81] found that Cbl
improved handgrip and tenderness compared to NSAID
treatment. Regarding effect on the CNS, intramuscular
injection of high doses of Cbl improved muscle action poten-
tial amplitude in a small double-blind trial in patients with
amyotrophic lateral sclerosis [89].
A successful example of local administration of Cbl to
reduce redox dysfunction and inflammation was published
by Macri et al. [90]. They found that eye drops containing
hyaluronic acid and vitamin B12 significantly decrease
markers of lipid peroxidation and inflammation, improving
dry eye symptoms. Although vitamin B12 is not classically
considered an antioxidant, more evidence accumulates
supporting a redox effect of Cbl. Since it is well tolerated
and no adverse effects have been reported, exploring further
the noncoenzyme and redox effects of Cbl is a promising
therapeutic avenue for cardiovascular, neurological, and
inflammatory diseases.
4. Enzyme Regulators and Mimetics
The use of stoichiometric antioxidant molecules presents
with the problem that they are finite. At the necessary site
they may be present in limited concentrations or may
not have been recycled after their redox reaction. Accord-
ingly, most cellular redox homeostasis is maintained by
enzymes [91]. As we have shown with micronutrients, cer-
tain antioxidants can increase enzyme production and
function aside from directly inactivating the reactive spe-
cies. Herein, we analyze several specific enzyme-directed
therapeutics and present an overview in Figure 1. Next,
we discuss the use of redox enzymes, enzyme mimics,
and enzyme regulators.
4.1. NADPH Oxidase Inhibitors.Nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidases (NOX) are a group of
transmembrane enzymes that generate superoxide (O2
•−) by
transferring electrons from NADPH across a membrane to
reduce molecular oxygen [92]. Accordingly, NOX enzymes
are present in the plasma membrane, endoplasmic reticulum,
mitochondrial membrane, and nuclear membrane, as well as
at focal adhesions [93] and invadopodia [94]. In total, there
are seven NOX isoforms termed NOX1-5 or DUOX1-2.
NOX enzymes are physiologically crucial for the immune
response and during angiogenesis; these functions along with
enzymatic regulation and localization have been reviewed in
extensive detail elsewhere [95]. Pathologically, dysregulated
NOX enzymes have been implicated in various cancers
[96, 97], neurodegenerative diseases [98], cardiovascular
diseases [99], and renal disease [100].
Due to the association of dysregulated NOX with disease
onset, it was fitting to pursue direct NOX inhibition as a ther-
apeutic. Triazolopyrimidine derivatives (VAS) and pyrazolo-
pyridine dione derivatives (GKT) are two efficacious small
molecule inhibitors that have been reported. VAS and GKT
successfully mitigate ROS formation and damage in in vitro
and in vivo models of disease [101–105]. These two families,
and others not covered in this section, have been extensively
reviewed elsewhere [106].
Specifically, GKT137831 is a NOX 1 and 4 inhibitor that
has been reported to mitigate renal disease [105], attenuate
diabetic nephropathy [102], and suppress cardiac fibroblast
activity associated with hypertensive heart disease [104]. A
randomized, double-blind, placebo-controlled phase II trial
using GKT137831 for treating type 2 diabetes with nephrop-
athy was concluded in 2015 (NCT02010242). The drug
developer, Genkyotex, reported that GKT137831 was safe
and significantly reduced liver enzyme and inflammatory
marker levels, with the results unpublished as of June 2017.
Currently, Genkyotex is finalizing a phase II study design to
treat the liver disease primary biliary cholangitis with
GKT137831.
Meanwhile, VAS2870 a NOX 1, NOX 2, and NOX 4
inhibitor has been reported to have protective properties
against brain ischemia in mice [101] and to reduce ROS pro-
duction and radiation-induced phenotypic changes in
human pulmonary artery endothelial cells [103]. One chal-
lenge for translating the success of VAS molecules to the
clinic is their low solubility. Hecht et al. [107] have poten-
tially solved this issue by developing a method that utilizes
spray drying, microemulsification, and cyclodextrin incorpo-
ration to enhance the solubility and stability of VAS3947 as a
model VAS molecule, for oral administration. Ongoing stud-
ies with these two classes of molecules will offer a greater
understanding of their pharmacological efficacy and the
value of targeted NOX inhibition in disease treatment or
prevention.
4.2. Nitric Oxide Synthase Inhibitors. Nitric oxide synthase
(NOS) represents a group of enzymes that utilize molecular
oxygen and NADPH to oxidize L-arginine producing
L-citrulline and nitric oxide (•NO). There are three NOS iso-
forms termed neuronal NOS (nNOS or NOS I), inducible
NOS (iNOS or NOS II), and endothelial NOS (eNOS or
NOS III). Exceptions to the general locations and regulatory
mechanisms for each isoform have been extensively reviewed
elsewhere [108], but generally, nNOS is found throughout
the central (CNS) and peripheral (PNS) nervous systems
where •NO is implicated in aspects of synaptic plasticity
and cellular communication; iNOS is typically found in cells
of the immune system where •NO is responsible for the cell’s
cytotoxic properties; eNOS is mostly expressed in endothelial
cells where •NO causes vasodilation and vasoprotection and
prevents platelet aggregation. Therapeutic approaches have
been aimed at inhibiting iNOS.
Initially, NOS inhibitors aimed to displace the enzymatic
substrate arginine but were clinically ineffective and even
increased mortality in the case of L-NMMA treatment for
septic shock [109]. To date, the most successful NOS
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inhibitor is 4-amino-tetrahydrobiopterin (VAS203), devel-
oped by Vasopharm, which is an analogue of the redox-
sensitive NOS cofactor tetrahydrobiopterin rather than an
arginine analogue [110]. VAS203 is an allosteric iNOS inhib-
itor and is being trialed for the treatment of traumatic brain
injury (TBI). TBI has been shown to cause increased iNOS
activity in the brain due to a compromised blood-brain
barrier, aside from other major complications [111]. An
exploratory phase II placebo-controlled, randomized trial
named NOSTRA-II determined that VAS203 may have neu-
roprotective properties and can be safely administered,
although there was reversible kidney damage reported in
several patients at the highest tested dose (30mg/kg)
[110]. In light of these findings, a phase I trial to assess
renal function impairment in healthy volunteers was con-
cluded in early 2017 with results unreported so far
(NCT02992236). As of June 2017, NOSTRA-III—the
placebo-controlled, randomized, double-blind phase III
trial—is underway to evaluate the efficacy of VAS203 infu-
sions on clinical outcomes of patients with moderate to
severe TBI (NCT02794168).
4.3. Superoxide Dismutase Mimetics. Superoxide dismutase
(SOD) is a group of metal-containing enzymes that convert
superoxide (O2
•−) to hydrogen peroxide (H2O2) and/or
molecular oxygen. In humans, there are cytosolic (SOD1)
and extracellular (SOD3) isoforms which utilize copper and
zinc as cofactors while the mitochondrial (SOD2) isoform
uses manganese as the cofactor. Manganese porphyrins
(MnP) are among the most prominent SOD mimics
developed to date. MnPs are made up of a macrocyclic ring
structure with manganese found at the center. Other SOD
mimics also have similar structures but house a different







































































Figure 1: A scheme depicting cellular sites of action of several redox interventions. ARE/EpRE: antioxidant response element/electrophile
responsive element; CoQ10: coenzyme Q10; CXA-10: 10-nitro-oleic-acid formulation; DMF: dimethyl fumarate; ER: endoplasmic
reticulum; GKT: GKT137831; GPx: glutathione peroxidase; GSH: glutathione; IAB: N-iodoacetyl-N-biotinylhexylenediamine; MnP:
manganese porphyrins; NAC: N-acetylcysteine; NOS: nitric oxide synthase; NOX: NADPH oxidase; NQO1: NAD(P)H quinone
dehydrogenase 1; Nrf2: nuclear factor erythroid 2-related factor 2; RNS: reactive nitrogen species; ROS: reactive oxygen species; SFN:
sulforaphane; SOD: superoxide dismutase.
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other prominent mimetics’ synthesis, structure, kinetics, and
potential therapeutic benefits has been extensively reviewed
[112]. The therapeutic efficacy of MnPs is heavily dependent
on the redox environment at the time of administration. For
instance, MnP administration at the onset of diabetes inhib-
ited oxidative damage in a rat model [113]. When adminis-
tered after the onset of diabetes, however, the same MnP
actually increased oxidative damage [114].
GC4419 is a promising new MnP-like SOD mimetic
highly specific for reacting with O2
•−. GC4419 has been
shown to rescue cell clonogenicity of both a SOD2-null
human embryonic kidney cell line [115] and radiation or
chemotherapy-treated primary human dermal fibroblasts
[116]. Intravenous delivery of GC4419 is currently in a phase
II clinical trial for alleviating radiation-induced oral mucosi-
tis in patients with head and neck cancer (NCT02508389).
Galera Therapeutics Inc. is also assessing the tolerability
and pharmacokinetics of another SOD mimetic, GC4711,
given orally compared to intravenous GC4419 in healthy vol-
unteers (NCT03099824). BMX-001 is a MnP currently in a
phase I clinical trial for glioblastoma patients undergoing
radiation therapy (NCT02655601). Additionally, a continu-
ous infusion of MnP AEOL 10150 using a subcutaneously
implanted osmotic pump was able to significantly reduce
radiation-induced injury in a rat model [117] and has proven
to be beneficial in a nonhuman primate radiation-induced
injury model [118]. As of 2017, Aeolus Pharmaceuticals
Inc. is working on moving AEOL 10150 into clinical trials.
Of note, MnPs often can react with various species and
moieties besides O2
•− which expands their potential out-
side of being just a SOD mimetic but also complicates
their utility.
4.4. Catalase Delivery. Catalase is an antioxidant enzyme that
catalyzes the disproportionation of H2O2 to O2 and H2O; it
decreases neuroinflammation and attenuates neurodegenera-
tion in the CNS.
An important component of many metabolic and inflam-
matory diseases of the CNS involves inflammation [119].
These include Alzheimer’s and Parkinson’s diseases (AD
and PD) [120–122], stroke [123, 124], traumatic brain injury
(TBI), multiple sclerosis (MS), age-related macular degener-
ation (AMD), prion disease, meningitis, encephalitis, human
immunodeficiency virus- (HIV-) associated neurocognitive
disorders [125, 126], epilepsy, brain cancer, lysosomal stor-
age diseases [127, 128], obesity [129, 130], and even mental
health disorders such as depression, autism, and schizophre-
nia. These diseases are often accompanied by the extensive
recruitment of immunocytes. Such inflammatory activities
are linked to microglial activation and its secretion of
neurotoxic factors. These include ROS and RNS leading to
oxidative stress and neuronal injuries [131–134]. Oxidative
stress affects neuronal, astrocyte, and microglia function
by inducing ion transport and calcium mobilization and
activating apoptotic programs. Apoptosis and excitotoxicity
are principal causes of mitochondrial-induced neuronal
death. Therefore, the need for delivery of potent antioxi-
dants, in particular, catalase to affected brain tissues cannot
be overstated.
The administration of catalase has been shown to rescue
the primary cultured cerebellar granule cells in in vitro
models of PD [135, 136]. Thus, addition of catalase to
cerebellar granule cells treated with a toxin, 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) that causes a
severe and irreversible parkinsonian syndrome in humans
and in nonhuman primates [137], resulted in enhancing their
viability by 75% compared to the control cells. Regrettably,
the blood-brain barrier (BBB) severely restricts the transport
of this potent antioxidant to the brain. Although small
lipophilic molecules (MW< 400 kDa) can cross the BBB in
pharmacologically significant amounts, effective concentra-
tions of lipid-insoluble drugs (polar molecules and small
ions), as well as high molecular weight compounds (peptides,
proteins, and nucleic acids), cannot be delivered to the CNS
within the limits of clinical toxicity. The inability of most
potent therapeutics to cross the BBB following systemic
administration necessitates the need to develop unconven-
tional, clinically applicable drug delivery systems for the
treatment of brain disorders. Smart, biologically active
vehicles are crucial to accomplishing this challenging task.
To this end, immunocytes that include mononuclear
phagocytes (dendritic cells, monocytes, and macrophages),
neutrophils, and lymphocytes can carry nanoformulated
drugs as they readily home to disease sites. Using living cells
as drug delivery vehicles, takes advantage of their natural
carriage, storage, mobility, and secretory capacity. It offers
several benefits over common drug administration regimens;
these include targeted drug transport to disease sites, pro-
longed drug half-lives, time-controlled drug release, and
diminished drug immunogenicity and cytotoxicity profiles.
Thus, a cell-based delivery system to bring nanoformulated
catalase to affected brain regions was developed [138, 139].
The system rests in the abilities of blood-borne macrophages
to carry antioxidant proteins across the BBB to the inflamed
tissues. Using inflammatory response cells enables targeted
drug transport and prolonged circulation times [140], along
with reductions in cell and tissue toxicities. In addition, these
cells are capable of cell-to-cell transmission of drug-laden
nanoparticles that improves their therapeutic outcomes.
One of the main obstacles in utilizing these cells is
related to the fact that monocytes efficiently disintegrate
and digest all entrapped foreign particles. Therefore, it is
crucial to protect the activity of the drug inside this cell car-
rier [141]. To preclude macrophage-mediated enzyme degra-
dation, catalase was packaged into a block ionomer complex
with a cationic block copolymer, poly(ethyleneimine)-
poly(ethylene glycol) (PEI-PEG). Overall, the structure
and composition of protective nanocontainers play a crucial
role in the effectiveness of formulations for cell-based drug
delivery systems. For example, a recent study by one of us
indicates that structure of block copolymer used for catalase
nanoformulation (nanozyme), affects its cytotoxicity, load-
ing, and release capacities, as well as preservation of catalase
enzymatic activity inside cell-carriers [142]. Bone marrow-
derived macrophages (BMM) carried significant amounts of
catalase then slowly released the active enzyme over several
days [138]. The enzyme released upon stimulation of
nanozyme-loaded cell carriers decomposed microglial H2O2
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produced upon nitrated alpha-synuclein or tumor necrosis
factor alpha- (TNF-α-) induced activation in vitro. A sig-
nificant amount of catalase was detected in brains of mice
after transfer of BMM loaded with nanoformulated cata-
lase following MPTP intoxication. It was demonstrated
that such nanozyme-loaded BMM injected into MPTP-
intoxicated mice reduce neuroinflammation and attenuate
nigrostriatal degeneration [139]. This signified a neuropro-
tective effect of nanozyme-loaded monocytes in MPTP-
induced neurodegeneration.
Another approach to targeted cell-mediated brain deliv-
ery of catalase is to utilize macrophages transfected ex vivo
with a plasmid DNA (pDNA) encoding catalase [143].
Systemic administration of pretransfected macrophages
produced month-long expression levels of catalase in the
brain resulting in threefold reductions in inflammation and
complete neuroprotection in mouse models of PD. This
resulted in significant improvements in motor functions in
PD mice. Mechanistic studies revealed that transfected mac-
rophages secreted extracellular vesicles, exosomes, packed
with catalase genetic material, pDNA and mRNA, active
catalase, and NF-κB, a transcription factor involved in the
encoded gene expression. Exosomes efficiently transfer their
contents to contiguous neurons resulting in de novo protein
synthesis in target cells. Thus, genetically modified macro-
phages serve as a highly efficient system for reproduction,
packaging, and targeted gene and drug delivery to treat
inflammatory and neurodegenerative disorders [143]. Of
note, a proper differentiation of drug carriers into particular
subtypes may further boost the therapeutic efficiency of
cell-based drug formulations [144]. Alternatively, activated
macrophages phenotype (M2) utilized in these studies did
not promote further inflammation in the brain, resulting
in a subtle, but statistically significant effect on neuronal
regeneration and repair in vivo.
Even though this modality of antioxidant enzyme
delivery has not moved to clinical trials yet, it is a promising
approach to deliver redox-active enzymes in a targeted
manner and to overcome several of the obstacles related to
delivery of proteins and delivery to the CNS.
5. Small Molecule Antioxidants
Small (MW<250 kDA) molecule antioxidants have desirable
pharmacokinetic properties able to exponentially enhance
antioxidant defense by directly acting on signaling pathways
[145]. Phenolic groups dominate this class but there are
multiple other species with unique antioxidant properties
[146]. In this section, we will discuss some of the most
commonly used and already developed small molecule anti-
oxidants and highlight emerging formulations (Figure 1).
5.1. Electrophiles. Electrophilic small molecules are potent
activators of the nuclear factor erythroid 2-related factor 2
(Nrf2) pathway. Nrf2 is a transcription factor that induces
the production of antioxidant and detoxification enzymes
controlled by an enhancer sequence called the antioxidant
response element/electrophile responsive element (ARE/
EpRE). The identification of Nrf2 as the critical transcription
factor in this pathway was only recognized in 1997 [29]. This
discovery triggered tremendous progress in understanding
the increased efficacy of small molecule antioxidants in
therapeutic applications. Under homeostatic conditions,
Nrf2 is sequestered to the cytoplasm by the actin-bound
inhibitor Kelch-like ECH-associated protein 1 (Keap1).
Keap1 subjects Nrf2 to polyubiquitination and degradation
via the proteasome. During redox imbalance, or if the cell is
exposed to electrophilic small molecules, key cysteine resi-
dues on Keap1 are oxidized causing a conformational change
that releases Nrf2. Under these conditions, Nrf2 is able to
translocate to the nucleus where it forms heterodimers with
Maf proteins and binds ARE/EpRE. Nrf2 binding to ARE/
EpRE results in transcription of cytoprotective enzymes such
as catalase, glutathione S-transferase, NAD(P)H quinone
oxidoreductase 1, SOD 1, heme oxygenase 1, and manymore.
5.1.1. Sulforaphane. Sulforaphane (SFN) is an isothiocyanate
metabolite found in cruciferous vegetables, such as broccoli,
and is one of the most widely studied electrophilic Nrf2
inducers. The anticarcinogenic properties of broccoli were
attributed to SFN when it was first identified as a phase II
metabolic enzyme inducer in 1992 [147]. After the character-
ization of the Nrf2/Keap1 pathway, SFN was identified as a
Nrf2 inducer further describing its potential in anticancer
therapy [148]. Since then, oral administration of SFN has
been shown to improve behavioral symptoms of young
men with autism spectrum disorder [149] and is being
further evaluated for this condition (NCT02561481,
NCT02879110, and NCT02909959). SFN has also been
shown to improve fasting glucose in obese patients with dys-
regulated type 2 diabetes [150] and is currently in a phase II
clinical trial (NCT02801448). As a redox-based therapeutic,
SFN is making headway in animal models of atherosclerosis.
Angioplasty with stent placement is the most common
surgical intervention for treating atherosclerosis or a stenotic
vessel. A major complication following angioplasty is vessel
reocclusion or restenosis. Currently, restenosis is best
inhibited by chemotherapy-eluting stents, yet they create a
favorable local environment for thrombosis [151]. Yoo et al.
[152] showed that local application of SFN at the site of
arterial injury inhibits restenosis in an angioplasty-injury
rat model. This was attributed to the Nrf2-activating proper-
ties of SFN, which likely inhibits the phenotypic change in
vascular smooth muscles that drives restenosis. Multiple
other groups have since successfully inhibited restenosis
using SFN in similar animal models [153, 154]. One of us
has been studying local delivery of other electrophiles such
as cinnamic aldehyde as a therapy to inhibit restenosis.
Development of a delivery vehicle that specifically targets
the site of an atherosclerotic plaque could provide a novel
antioxidant approach for treating vasculopathies and
improving surgical outcomes and is the current focus of
our lab.
5.1.2. Dimethyl Fumarate. Dimethyl fumarate (DMF) is an
esterified fumaric acid that can inhibit NF-κB activation
[155]. DMF effectively increases relapsing-remitting multiple
sclerosis patient quality of life when administered orally as
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a delayed-release conformation, termed BG00012 [156]
(NCT00420212). DMF interacts with GSH under specific
conditions in the bloodstream which limits this absorption
route and bioavailability, justifying why recent studies
mostly use limited and/or low doses of DMF [157]. New
formulations of DMF or newly synthesized derivatives
could improve the pharmacokinetics of this compound
and provide useful new approaches.
5.1.3. Nitro-Oleic Acid. Nitro-oleic acid is one of the many
nitrated fatty acids naturally present in human and animal
tissues. Nitrated fatty acids result from •NO-derived species
reacting with unsaturated fatty acids resulting in •NO2
addition at a double bond [158]. Nitro-oleic acid has been
shown to have cytoprotective properties through Nrf2 and
PPARγ activation and NF-κB inhibition [158]. CXA-10 is
an orally administered 10-nitro-oleic-acid compound
developed by Complexa Inc. CXA-10 has been trialed
in five phase I clinical trials related to kidney injury as
of 2017 (NCT02313064, NCT02127190, NCT02248051,
NCT02460146, and NCT02547402) with differentiated safety
in over 100 subjects reported as well as activation of target
genes and inhibition of disease-related fibrotic and inflam-
matory biomarkers. Notably, the metabolic profile of patients
in NCT02127190 has recently been characterized [159].
CXA-10 is set to enter phase II trials in 2018 for the treatment
of pulmonary arterial hypertension and focal segmental glo-
merulosclerosis, two life-threatening diseases with a severely
poor prognosis. These and future trials using nitrated lipids
may yield effective redox-based therapies.
5.1.4. Synthetic Electrophiles. Recently, there has been a surge
in development of ARE-/EpRE-inducing molecules. Such
molecules include N-iodoacetyl-N-biotinylhexylenediamine
(IAB) which modifies Keap1 [160] but so far has a minimum
effect on Nrf2 activation due to cytotoxicity and engagement
with intracellular proteins [161]. Dai et al. [162] recently
showed that several new formulations of Pyrazino[2,1-a]iso-
quinolin analogues, compounds originally designed for their
antifungal properties [163], have potential as inducers of
the Nrf2 pathway. Future studies using novel formulations
may yield exciting therapeutics in the upcoming years.
Moreover, testing new synthetic electrophilic compounds
using novel platforms for targeted delivery could offer sig-
nificant advances in redox medicine.
5.2. Nitric Oxide and Related Compounds. •NO is a small
nitrogen-centered free radical gas that can diffuse several cell
diameters from its production site. As mentioned above, it is
synthesized by nitric oxide synthases (NOS). It serves as a
neurotransmitter involved in memory and learning, and as
a signaling molecule controlling vascular tone, cell prolifera-
tion, and cell survival. During inflammation an inducible
form of NOS (iNOS) produces large quantities of •NO
involved in host protection against pathogens. Because of
its role in vascular homeostasis, its potential therapeutic role
in vascular disease has been extensively studied and is
reviewed elsewhere [164]. Direct inhalation of •NO is the
simplest way to deliver it. Inhaled •NO has been clinically
used to treat pulmonary hypertension and acute respiratory
distress syndrome. However, a recent systematic review
analyzing 14 different trials shows that even though inhaled
nitric oxide improves oxygenation, there is no reduction in
mortality [165]. On the other hand, inhalational •NO appears
to be beneficial for respiratory failure in terms of infants after
meta-analysis of 16 studies [166]. •NO reduced mortality
and/or use of extracorporeal membrane oxygenation. More-
over, inhalational •NO reduces development of chronic lung
disease and use of extracorporeal membrane oxygenation in
newborns with persistent pulmonary hypertension [167].
Similarly, Miller et al. [168] conducted a randomized study
in infants with pulmonary hypertension after congenital
heart surgery. They found that inhalation of •NO lessens
the risk of pulmonary hypertensive crises and shortens
postoperative recovery [168].
Since •NO is highly reactive, inhalational •NO is
mostly a local intervention to the airways. When it comes
to systemic administration, different strategies have been
used to increase •NO: administration of its precursors
L-arginine, use of •NO donors, or use of other •NO bioactive
compounds such as nitrates, nitrite, or S-nitrosothiols. A
systematic review in 2017 that included 5 completed clinical
trials assessing the use of glyceryl trinitrate in patients with
stroke concluded that there is no evidence to recommend
use of this drug in stroke [169]. The amount of preclinical
data suggesting a beneficial effect of increasing •NO for the
treatment of vascular disease has not led to a successful
clinical translation. Even though there are several attempts
to increase •NO via systemic administration of L-arginine
or nitric oxide donors, they have failed to improve vascular
outcomes (reviewed in [164] and [170]). A large prospective
multicenter, randomized trial studying the effect of •NO
donors on restenosis after balloon angioplasty showed a
modest improvement on angiographic restenosis but no
differences in clinical outcomes [171]. These negative results
highlight the issue of attempting to treat a localized •NO
deficiency at sites of arterial disease via a systemic approach.
Hence, numerous attempts to deliver bioactive •NO locally
aim at overcoming the problems with systemic delivery.
Endolumenal delivery of •NO via a permeable balloon cathe-
ter inhibits restenosis in the rat carotid balloon injury model
[172]. We have shown that an S-nitrosated nanofiber
targeted to sites of arterial injury significantly inhibits reste-
nosis in the rat balloon carotid injury model [173].
Further evidence that targeted or localized approaches
result in successful clinical application of •NO-based thera-
pies is provided from fields that lend themselves to formula-
tions for local delivery. One such field is dermatology, and
the anti-inflammatory and antimicrobial properties of •NO
show promise to treat acne vulgaris [174]. Results of a phase
II clinical trial (NCT01844752) show that a topical formula-
tion of •NO decreases inflammatory and noninflammatory
lesions in subjects with acne vulgaris [175].
5.3. Flavonoids. Flavonoids are a group of naturally occurring
compounds found in many fruits and vegetables as well as
beverages such as tea and wine. The flavonoid active com-
pounds are secondary metabolites that have been proven
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beneficiary in protecting against atherosclerotic disease
progression [176]. Flavonoids were initially identified for
their direct scavenging properties but recent findings point
out that the indirect antioxidant effects are of greater biolog-
ical relevance and better support the use of these compounds
as therapeutics [177]. Accordingly, flavonoids have been
ascribed to anti-inflammatory, anticancer, and antithrom-
botic properties with dose-dependent effects [178].
5.3.1. Curcumin. Curcuma longa, turmeric, is the yellow-
pigmented spice commonly used in curries that is comprised
of naturally occurring phenolic compounds called curcumi-
noids. Curcumin is the most abundant of the curcuminoids
and is classified as a linear diarylheptanoid with multiple
functional groups. In mice, curcumin has been shown to
induce Nrf2 nuclear translocation and induction of ARE/
EpRE signaling [179]. Curcumin has been shown to inhibit
gastric tumor growth by disrupting cellular bioenergetics
[180] and to reduce the atherogenic and dyslipidemic panel
in patients with chronic disease [181, 182]. Multiple studies
show adjunct supplementation of curcumin with other active
ingredients induces redox homeostasis in metabolic syn-
drome [183]. Of note, curcumin has been extensively
pursued as a therapeutic with over $150 million in federal
funds linked to biomedical studies, yet no conclusive thera-
peutic effects in humans have been determined to date
[184]. Nelson et al. [184] recently published an extensive
review describing some considerations to explain the pitfalls
of using curcumin. In general, the poor absorption of curcu-
min and limited abundance of the active compound may
hinder its therapeutic potential as a systemic agent. Further-
more, they classify curcumin as a pan-assay interference
compound which may show activity in an assay by interfer-
ing with the readout rather than by the specific compound/
target interaction the assay aims to assess. Nevertheless,
because of its lipophilic characteristics, curcumin could still
be considered a good agent for synergic localized or targeted
therapy if better formulations arise. Indeed, nanoparticle-
encapsulated curcumin has been shown to have antimicro-
bial properties and to promote wound healing in an in vivo
murine wound model [185].
5.3.2. Quercetin. Quercetin is a polyphenolic, pigmented
flavonoid found in capers and onions that acts as an ROS
scavenger. Quercetin has been proposed to have antioxidant
effects in inducible vascular models of disease [186, 187],
while also exhibiting anti-inflammatory and antineoplastic
properties in several other models [188–190]. Unfortunately,
most flavonoids are not readily absorbed by the human intes-
tine which severely limits the bioavailability and overall
therapeutic potential of quercetin [191]. It has failed to
exhibit the anticipated preventative effects on serum phos-
pholipids in healthy subjects as a supplement over an
8-week period [192]. Also, no significant changes in
endothelial function or •NO production were reported after
50–400mg doses of water-dissolved quercetin extract were
given to healthy subjects [193] (ACTRN12615001338550).
It has been reported that a food matrix, as in onion powder
rather than extract, significantly increases the bioavailability
of quercetin in animals and humans [194]. Burak et al.
[195] recently showed that the use of concomitant onion skin
extract, instead of quercetin dehydrate alone, significantly
increased the oral bioavailability of quercetin in healthy
subjects. Extracting quercetin during food processing may
be the factor limiting bioavailability of this flavonoid. As
such, combinatorial therapy with other antioxidants, as has
recently been trialed [196], may enhance quercetin delivery
and overall benefit.
5.3.3. Resveratrol. Resveratrol is a natural phenol found in
berries. It is the most studied flavonoid in scientific research
and has the potential to induce Sirtuin-1 activity [197] and
modulate Nrf2 [198] and NF-κB [199]. In vitro studies indi-
cate anti-inflammatory effects from resveratrol in multiple
cell lines [200, 201]. In human keratinocytes, it has been
shown to reduce H2O2-induced production of ROS [202]. It
also has proven preventive antioxidant therapeutic effects in
multiple animal injury models [203–205]. In chickens,
resveratrol induces redox balance via heat shock protein reg-
ulation in immuno-competent tissues [206]. In clinical stud-
ies, oral supplementation in adult smokers significantly
decreased acute phase markers and triglycerides but did not
alter chronic disease markers, weight, and blood pressure
[207]. Topical application of resveratrol and vitamin E
increased skin pigmentation and elasticity by altering heme
oxygenase 1 and other collagen-specific targeting genes
[208]. Orally administered resveratrol reduced cardiovascu-
lar disease risk in hypercholesterolemia patients and also
increased serum vitamin E levels [209]. Apostolidou et al.
[209] highlight the synergistic properties of resveratrol and
vitamin E in decreasing cardiovascular disease risk. This
illustrates the great potential that flavonoids, specifically res-
veratrol, might have as a joint therapy with other antioxidant
molecules.
5.4. Thiol Molecules
5.4.1. Glutathione. Glutathione (GSH) is a nonprotein, tri-
peptide thiol and one of the most abundant antioxidants in
the body. In its reduced form, GSH is integral for cellular
metabolism and maintaining cellular redox homeostasis.
Work done by Mischley et al. [210] suggested that intranasal
delivery may be able to augment GSH levels within the
nervous system of patients with Parkinson’s disease. In a
follow-up phase II trial, however, there was no significant
improvement in motor function from intranasal GSH deliv-
ery compared to the placebo [211]. In 2015, Schmitt et al.
[212] showed that sublingual GSH was absorbed more
effectively than oral supplementation by bypassing hepatic
metabolism, potentially revealing a compelling new delivery
approach. Several clinical trials assessing the benefit of oral
GSH delivery are currently underway for growth improve-
ment in children with cystic fibrosis (NCT03020719) and
overall health of adults with a history of malnutrition
(NCT03166371). Future work will dictate whether the thera-
peutic benefits of GSH can be through isolated administra-
tion or will continue to rely on intracellular upregulation by
exogenous agents.
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5.4.2. N-Acetylcysteine. N-acetylcysteine (NAC) is a prodrug
thiol and precursor for cysteine and GSH. NAC treatment
has been promising in in vitro [213] and in vivo [214] models
but has fallen short in clinical trials similarly to most other
antioxidants. NAC was ineffective in randomized clinical
studies of arterial disease [215] and in attenuating nephro-
toxicity [216]. Kazemi et al. [217] found no association
from a high dose of prophylactic NAC given orally before
and after surgery in preventing postoperative atrial fibrilla-
tion. A clinical trial evaluating NAC administered with
amiodarone, which helps regulate heart rhythm, in pre-
venting atrial fibrillation after thoracic surgery is currently
in phase III (NCT02750319). Synergic NAC administra-
tion has been promising in treating infection [218] and
reflux disease [219]. Trials using NAC with L-carnitine
for polycystic ovary syndrome (NCT03164421) and with
the drug minocycline for the treatment of bipolar depres-
sion (NCT02719392) are currently underway. As of 2017,
there are over 70 other ongoing clinical trials using NAC
as a sole therapeutic or together with other antioxidant
molecules or drugs which will broaden our understanding
of this unique prodrug.
5.5. Other Scavenging Molecules
5.5.1. Coenzyme Q10 and MitoQ10. Coenzyme Q10 (CoQ10)
is a lipid-soluble ubiquinol antioxidant with high functional-
ity in the Golgi apparatus and endoplasmic reticulum [220].
CoQ10 has been shown to reduce oxidative stress by modu-
lating UBIAD1 and eNOS enzymatic activity in cardiovas-
cular tissues [221]. A research group from Linköping
University in Sweden has published multiple papers using
oral administration of CoQ10 in clinical studies. The
results show a direct effect on serum selenium levels which
corresponds with decreased cardiovascular mortality rate in
elderly patients [222]. CoQ10 in joint administration with
selenium modified over 100 different microRNA expression
levels in healthy elderly patients [223]. Lastly, the joint
administration with selenium for 4 years increased insulin-
like growth factor-1, which has implications of anti-
inflammatory and antioxidative effects, further explaining
the observed reduction in cardiovascular mortality in these
trials [224]. Yet, a 300mg oral dose of CoQ10 12 hours post-
procedure did not reduce periprocedural myocardial injury
in patients with elective percutaneous coronary interventions
but did decrease C-reactive protein [225]. MitoQ10 is a 3rd
generation derivate of CoQ10 that has an added positive
charge with direct targeting for the mitochondria. Even
though this approach does not target a specific organ or
tissue, it directs the redox intervention to a specific organelle.
MitoQ10 administered in drinking water jointly with
Losartan prevented hypertensive disease and consequent
rat myocardial hypertrophy [226]. In a clinical trial, orally
administered MitoQ10 showed no therapeutic benefit as a
Parkinson’s disease-modifying therapy [227]. MitoQ10 is
currently in clinical trials for improving physiological func-
tion of middle-aged and older adults (NCT02597023), atten-
uating chronic kidney disease (NCT02364648), and reducing
fatigue experienced by patients with multiple sclerosis
(NCT03166800). The benefits of these two therapeutics
appear yet to come, especially for MitoQ10 as it advances
into promising clinical trials.
5.5.2. Ebselen. Ebselen is a synthetic selenoorganic molecule
with antioxidant, anti-inflammatory, antimicrobial, and anti-
fungal properties. This molecule is capable of catalytically
scavenging hydrogen peroxide and organic hydroperox-
ides, at the expense of cellular thiols, thus mimicking glu-
tathione peroxidase [228]. Additionally, ebselen can react
with ONOO− (k= 106M−1 s−1) providing another possible
mechanism of redox modulation [229]. Moreover, the ability
of ebselen to react with cellular thiols makes ebselen a weak
electrophile capable of activating Nrf2 [230]. SPI-1005 is an
oral formulation of ebselen developed by Sound Pharmaceu-
ticals Inc. that has undergone phase I trials for hearing loss
(NCT01452607) and Meniere’s disease (NCT02603081)
and phase II trials for preventing noise-induced tempo-
rary auditory threshold shifts (NCT01444846) [231]. Cur-
rently, ebselen is in phase II trials to prevent ototoxicity
(NCT02819856), as well as noise-induced (NCT02779192)
and chemotherapy-induced (NCT01451853) hearing loss.
Preclinical evidence suggested that ebselen improves insu-
lin secretion and pancreatic islet viability in murine
models of diabetes [232, 233]; however, ebselen failed to
improve glycemia and vascular function in a small clinical
trial with diabetic patients [234]. Importantly, this trial
measured redox markers and showed that the ebselen
dose and regimen used did not reduce any systemic
markers of oxidative stress, suggesting that redox regula-
tion was not achieved. The failure of this trial should
not be taken to imply that redox imbalance is not at the
core of the disease. Rather, as the redox state was not
altered, this suggests that a wrong dose, improper admin-
istration route, or perhaps even the wrong redox-active
molecule was used. Ongoing work with different formula-
tions of selenoorganic molecules [235] may yield new and
interesting therapeutics.
5.5.3. Edaravone. Edaravone is a synthetic reactive species
scavenging antioxidant previously named MCI-186. Edara-
vone has been reported to specifically quench hydroxyl
radicals, thus preventing lipid peroxidation, and has been
used for the treatment of ischemia-reperfusion injury in
Japan for more than a decade [236]. Edaravone was
rebranded as Radicava in 2017 after its approval by the
U.S. Food and Drug Administration (FDA) for the treat-
ment of amyotrophic lateral sclerosis (ALS) [237], a rare
neurodegenerative disease that effects voluntary muscle
movement. This designation was made after the conclu-
sion of the final phase III trial in October of 2017
(NCT01492686). Radicava treatment significantly reduced
the rate of disability progression experienced by patients
with ALS. The FDA approval of an antioxidant molecule
shows promise that identifying the proper disease and
patient population for a given molecule can result in a
successful drug campaign and, more importantly, in an
effective redox-based therapy.
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6. Conclusion
A causal relationship linking redox dysfunction with disease
would predict successful translation to the clinic of therapies
aimed at restoring redox homeostasis. However, the com-
plexity of cellular redox reactions continues to thwart the
utility of antioxidants as effective therapeutics in disease
prevention and treatment. The first trials aimed at restoring
redox homeostasis utilized antioxidants for their direct
scavenging and redox cycling properties but were largely
unsuccessful. Current evidence suggests that using molecules
to upregulate endogenous antioxidant enzyme expression
can have useful therapeutic benefits. Likewise, inhibition of
ROS/RNS producing enzymes or inhibiting pathways that
promote excess ROS/RNS generation could ultimately yield
a greater efficacy than attempting to scavenge these species
directly. Early failures of redox-active molecules in clinical
trials may reflect the wrong choice of therapeutic, the wrong
dose, or wrong selection of a patient population that would
benefit the most from the intervention. Not accounting for
these possibilities might lead to the conclusion that redox
dysfunction is not part of the disease etiology. Importantly,
few studies actually assess the effect of the redox intervention
on redox biomarkers. If an antioxidant fails to improve
primary outcomes, it is important to know if it actually
affects redox markers. If the intervention does not improve
redox status, then it is likely that the selection of drug, dose,
or route of administration was not ideal. This issue does
not have a clear solution since there is not a consensus as to
what biomarkers to use when assessing redox function
in vivo. Having some evidence that the tested drug actually
improves redox homeostasis, however, allows for the identi-
fication of a subset of patients that are more likely to benefit
from the redox intervention. For example, the use of tirapa-
zamine, a reductively activated drug to potentiate chemo-
therapy in patients with squamous cell carcinoma, showed
a promising significant effect in patients with hypoxic tumors
[238]. However, in a large phase III trial without selection for
hypoxia, addition of tirapazamine to chemoradiotherapy
showed no improvement in outcomes [239]. This highlights
the need to identify the patient population that is most likely
to benefit from the intervention. Failure to identify this
subpopulation could dilute the patient pool potentially
masking beneficial effects. Similarly, the example shows the
importance of measuring the specific conditions related to
the expected mechanism of action. Current studies address
several of these issues. Importantly, many successful clinical
trials have exploited local delivery or a targeted effect to
specific cells. The realization that local and targeteddrugdeliv-
ery could directly address the problem of systemic effect of
redox therapies opens a new and exciting avenue for transla-
tional redox research. As the drug delivery field develops new
and better ways to precisely target therapeutic payloads to tis-
sue sites, we can specifically address local redox dysfunction.
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